Tissue cross-reactivity (TCR) studies are an important aspect of pre-clinical development of therapeutic antibodies. Non-target specific binding to human tissue can result in serious consequences when pharmacologically active antibodies (Ab) are used to treat diseases. Therefore, prior to Phase I clinical trials, cross-reactivity studies of therapeutic Ab candidates are performed to identify cross-reactive or non-target tissue binding, which in turn provides important information about the immunological properties of the candidate antibody therapeutics.https://www.creative-biolabs.com/immuno-oncology/tissue-cross-reactivity-studies.htm
